

Theo Crosson, J Appl Bioinforma Comput Biol 2017, 6:4
DOI: 10.4172/2329-9533-C1-002

JOINT EVENT

9th International Conference and Expo on

Proteomics and Molecular Medicine

9th International Conference on

8

Bioinformatics

November 13-15, 2017 Paris, France

Fusion protein raised antibodies for evaluating mass spectrometry results

Theo Crosson

Proteintech Group Europe, UK

Proteomics studies often rely on the use of antibodies. Their ability to bind any protein makes them powerful tools of use for quantification, detection and characterisation of proteins. In particular, antibodies have been increasingly used in these past years for mass spectometry applications. Proteintech, founded by a group of scientists in 2002, is committed to manufacturing high quality antibodies in-house. Using whole-protein approach, longer time of immunization and stringent validation procedures, Proteintech has been able to support research in proteomics. Its antibodies have been used for publications involving mass cytometry, IP-MS and target evaluation from mass spectometry.

Biography

Theo Crosson is the account manager for France territory at Proteintech. Theo has studied biology and biotechnology at the ENSTBB in Bordeaux where he got an engineering degree. He has worked in research in Next Generation Sequencing for a year at New England Biolabs. He then completed his education with a specialized master in biotech management at the ESC Grenoble. He is now working for Proteintech, a company committed to providing high-quality antibodies produced and validated in-house, with the aim of assisting French researchers in their use of antibodies.

theo@ptglab.com

Notes: